2025-09-11 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX), incorporating the provided data.

**Disclaimer:** This analysis is based solely on the information provided and should not be considered financial advice.  Do your own thorough research before making any investment decisions.

## RXRX: Recursion Pharmaceuticals Inc. Analysis

Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -46.84%
*   **VOO Cumulative Return:** 39.61%
*   **Absolute Divergence:** -86.0 (RXRX significantly underperformed VOO)
*   **Relative Divergence:** 1.2 (This indicates RXRX is near the bottom of its historical range of divergence from the S&P 500.)

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha   | Beta | Cap(B) |
|------------|--------|--------|---------|------|--------|
| 2021-2023  | 5.0%   | 73.6%  | -5.0%   | 0.0  | 4.2    |
| 2022-2024  | 0.0%   | 73.6%  | -30.0%  | 0.0  | 2.9    |
| 2023-2025  | 5.0%   | 73.6%  | -41.0%  | 0.0  | 2.0    |

**Analysis:**

*   **Underperformance:** RXRX has significantly underperformed the S&P 500, showing a large negative divergence.  The relative divergence suggests that this underperformance is near its historical worst.
*   **Alpha:** The consistently negative alpha figures indicate that RXRX is underperforming relative to its benchmark, even after accounting for market risk.
*   **Beta:** The beta of 0.0 suggests that RXRX's price movements are not correlated with the broader market.
*   **MDD:** A high maximum drawdown (73.6%) across all periods shows the stock has experienced substantial declines from peak to trough, indicating high volatility and risk.
*   **Cap(B):** The decline in market capitalization from 4.2B to 2.0B over the given periods reflects a decrease in the company's overall value.

**2. Recent Stock Price Action**

*   **Current Price:** $4.699
*   **Last Market Data:** Price: $4.54, Previous Close: $4.70, Change: -3.4% (significant drop)
*   **5-day Moving Average:** $4.616
*   **20-day Moving Average:** $4.9712
*   **60-day Moving Average:** $5.3242

**Analysis:**

*   The current price is below all moving averages, indicating a downtrend.
*   The recent drop of -3.4% is a significant movement and could be a reaction to news or overall market sentiment.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3261 (Low Risk) - Although classified as "Low Risk" it's close to being in the "Medium Risk" range.
*   **RSI:** 34.40 (Approaching Oversold) - Suggests the stock may be oversold and could be due for a bounce.
*   **PPO:** -0.3832 (Negative) - Indicates the price is below its moving average, confirming the downtrend.
*   **Hybrid Signal:** Cash_70%_Sell (70% holdings) -  The algorithm is recommending selling a significant portion of holdings and moving to a high cash position (70%).  This is triggered by the MRI of 0.34 and is a cautionary signal.
*   **Delta_Previous_Relative_Divergence:** 1.2 (+) - Indicates a recent short-term upward movement, although it may be a temporary correction in a longer downtrend.
*   **Expected Return:** -2181.9% - This extremely negative number suggests a highly unfavorable long-term outlook compared to the S&P 500.

**Analysis:**

The technical indicators paint a mixed picture. While the RSI suggests a possible short-term bounce, the PPO, hybrid signal, and extremely negative expected return are concerning. The recent price drop reinforces the negative sentiment.

**4. Recent News & Significant Events**

*   **Rallybio Equity Milestone:**  A positive, albeit potentially small, influx of capital.
*   **Motley Fool Articles:** These are mixed, with articles discussing both the potential downsides and upsides of investing in RXRX.
*   **REV102 Acquisition:** Expanding the rare disease pipeline is a positive strategic move.
*   **Nvidia-Backed AI Data Center Stock:** The mention of Nvidia is a positive association, as Nvidia is a leader in AI.
*   **Investor Conferences:** Participation in conferences can help raise awareness and potentially attract investors.

**Analysis:**

The news flow is mixed.  The acquisition and investor conferences are positive, while the Motley Fool articles highlight both the risks and potential rewards. The Rallybio milestone is a small positive.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (2.62)
*   **Target Price:** $6.47 (Average) / $10.00 (High) / $3.00 (Low)

**Analysis:**

Analysts are generally neutral on the stock, with a "Hold" consensus.  The wide range in target prices indicates significant uncertainty about the company's future prospects.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue     |
|------------|-------|-------------|
| 2025-08-05 | -0.41 | $0.02B     |
| 2025-05-05 | -0.50 | $0.01B     |
| 2024-11-06 | -0.34 | $0.03B     |
| 2024-08-08 | -0.40 | $0.01B     |
| 2025-08-05 | -0.40 | $0.01B     |

**Analysis:**

*   **Consistent Losses:** The company consistently reports negative EPS, indicating a lack of profitability.
*   **Fluctuating Revenue:** Revenue fluctuates, but generally remains low.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.02B   | -5.54%        |
| 2025-03-31   | $0.01B   | -47.31%       |
| 2024-12-31   | $0.00B   | -183.62%      |
| 2024-09-30   | $0.03B   | 53.69%        |
| 2024-06-30   | $0.01B   | 36.14%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-06-30   | $0.92B   | -18.70%   |
| 2025-03-31   | $0.93B   | -21.68%   |
| 2024-12-31   | $1.03B   | -17.29%   |
| 2024-09-30   | $0.52B   | -18.27%   |
| 2024-06-30   | $0.58B   | -16.69%   |

**Analysis:**

*   **Low Revenue:** Revenue remains relatively low.
*   **Unstable Profit Margins:** Profit margins are highly variable, with significant losses in some quarters.
*   **Negative ROE:**  Consistently negative Return on Equity (ROE) indicates the company is not effectively generating profits from its equity.
*   **Equity Fluctuations:** Equity has fluctuated, reflecting the company's financial performance.

**7. Overall Summary**

Recursion Pharmaceuticals (RXRX) is currently facing significant challenges.  It has significantly underperformed the S&P 500, reporting consistent losses, and exhibiting high volatility. While the company is expanding its pipeline through acquisitions and has a positive association with AI through Nvidia, the technical indicators and financial data suggest caution. The analyst consensus is neutral, but the wide range of price targets reflects uncertainty. The algorithm suggests a move to cash.

**Key Concerns:**

*   **Lack of Profitability:** Consistent negative EPS and ROE are major red flags.
*   **High Volatility:** The high maximum drawdown indicates significant risk.
*   **Underperformance:** Substantial underperformance compared to the S&P 500.
*   **Hybrid Signal:** Cash_70%_Sell Signal implies high level of risk and uncertainty

**Potential Positives:**

*   **AI Focus:**  The company's focus on AI in drug discovery is a potentially high-growth area.
*   **Pipeline Expansion:** The acquisition of REV102 demonstrates a commitment to growth.
*   **Cash Position:** While concerning, the recommendation to increase cash holdings may provide flexibility.

**Conclusion:**

Based on the provided data, investing in RXRX appears highly risky at this time. The company needs to demonstrate a clear path to profitability and sustainable growth to justify a more positive outlook.
